<font color="red">Systemic_3</font> <font color="red">hemodynamic_3</font> <font color="red">,_3</font> <font color="red">neurohormonal_3</font> <font color="red">,_3</font> <font color="red">and_3</font> <font color="red">renal_3</font> <font color="red">effects_3</font> of a steady - state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure . 
<br>
<br> BACKGROUND Human brain natriuretic peptide ( hBNP ) is a promising agent for the treatment of <font color="red">decompensated_1</font> <font color="red">cardiac_1</font> <font color="red">failure_1</font> <font color="red">._1</font> However , the <font color="red">systemic_2</font> <font color="red">hemodynamic_2</font> <font color="red">,_2</font> <font color="red">neurohormonal_2</font> <font color="red">,_2</font> <font color="red">and_2</font> <font color="red">renal_2</font> <font color="red">effects_2</font> of hBNP have been incompletely studied in human heart failure . 
<br> METHODS AND RESULTS The effects of a continuous 4-hour infusion of hBNP were determined in 16 decompensated heart failure patients in an invasive , randomized , double - blind , placebo - controlled study . Patients were evaluated during three 4-hour study periods : baseline , treatment ( placebo [ n = 4 ] versus hBNP 0.025 or 0.05 microgram / kg / min [ n = 12 ] ) , and post - treatment . <font color="red">Urinary_1</font> <font color="red">volume_1</font> <font color="red">losses_1</font> were replaced hourly to separate the vasodilatory and diuretic effects of hBNP . Two patients in the hBNP group were excluded from the analysis because of <font color="red">adverse_2</font> <font color="red">events_2</font> <font color="red">._2</font> <font color="red">hBNP_1</font> significantly ( P < .001 ) <font color="red">reduced_1</font> <font color="red">right_2</font> <font color="red">atrial_2</font> <font color="red">pressure_2</font> <font color="red">and_1</font> <font color="red">pulmonary_2</font> <font color="red">capillary_2</font> <font color="red">wedge_2</font> <font color="red">pressure_2</font> by approximately 30% and 40% , respectively . <font color="red">hBNP_1</font> also <font color="red">significantly_1</font> <font color="red">lowered_1</font> <font color="red">systemic_2</font> <font color="red">vascular_2</font> <font color="red">resistance_2</font> from 1722 + /- 139 to 1101 + /- 83 dynes.s.cm-5 ( P < .05 ) . These unloading effects of <font color="red">hBNP_1</font> produced a 28% <font color="red">increase_1</font> in <font color="red">cardiac_2</font> <font color="red">index_2</font> ( P < .05 ) with <font color="red">no_1</font> <font color="red">change_1</font> in <font color="red">heart_2</font> <font color="red">rate_2</font> <font color="red">._2</font> Compared to placebo , <font color="red">hBNP_2</font> <font color="red">decreased_1</font> <font color="red">plasma_3</font> <font color="red">norepinephrine_3</font> <font color="red">and_3</font> <font color="red">aldosterone_3</font> <font color="red">._3</font> <font color="red">Renal_3</font> <font color="red">hemodynamics_3</font> were <font color="red">unaffected_1</font> by hBNP ; however , most patients were <font color="red">resistant_1</font> <font color="red">to_1</font> <font color="red">its_1</font> <font color="red">natriuretic_1</font> <font color="red">effect_1</font> <font color="red">._1</font> 
<br> CONCLUSIONS 1 ) The predominant <font color="red">hemodynamic_1</font> <font color="red">effects_1</font> of hBNP were a decrease in <font color="red">cardiac_2</font> <font color="red">preload_2</font> <font color="red">and_2</font> <font color="red">systemic_2</font> <font color="red">vascular_2</font> <font color="red">resistance_2</font> <font color="red">._2</font> 2 ) hBNP also improved <font color="red">cardiac_3</font> <font color="red">output_3</font> <font color="red">without_1</font> <font color="red">increasing_1</font> <font color="red">heart_3</font> <font color="red">rate_3</font> <font color="red">._3</font> 3 ) <font color="red">Plasma_3</font> <font color="red">norepinephrine_3</font> <font color="red">and_3</font> <font color="red">aldosterone_3</font> <font color="red">levels_3</font> decreased during hBNP infusion . 4 ) hBNP is <font color="red">pharmacologically_1</font> <font color="red">active_1</font> <font color="red">and_1</font> <font color="red">has_1</font> <font color="red">potential_1</font> <font color="red">in_1</font> <font color="red">the_1</font> <font color="red">therapy_1</font> <font color="red">for_1</font> <font color="red">decompensated_1</font> <font color="red">heart_1</font> <font color="red">failure_1</font> <font color="red">._1</font>